The primary objective was to assess the acute and 3-month performance of the modular antitachycardia pacing (ATP)-enabled leadless pacemaker (LP) and subcutaneous implantable cardioverter-defibrillator (S-ICD) system, particularly device-device communication and ATP delivery.
Device infections (sometimes involving the pocket but more so when systemic) are associated with a high risk of mortality (8) .
To reduce complications related to transvenous leads, both the leadless pacemaker (LP) and the subcutaneous implantable cardioverter-defibrillators (S-ICDs) were introduced and have shown clinical efficacy and safety (9) (10) (11) (12) (13) . To date, these systems are only available for patients either requiring single-chamber right ventricular (RV) pacing or shock-only defibrillation therapy. Combined use of both devices could bring the benefits of leadless therapy to a larger patient population by providing both bradycardia pacing and defibrillation therapy. Limited evidence on the combined use of both devices has been reported in case studies (14, 15) . For patients in need of antitachycardia pacing (ATP) therapy, there are no leadless solutions available to date.
We recently reported the first proof-of-concept study of a unidirectional LP and S-ICD that can deliver bradycardia pacing, ATP, and defibrillation therapy (16) During the course of the study, development of the LP was ongoing, and improvements in the microprocessor and software were introduced; no changes were made to the design or shape of the LP, the delivery catheter, or the S-ICD.
IMPLANTATION PROTOCOLS. An ATP-enabled LP prototype was implanted in the RV apex, using a percutaneous, transfemoral approach through a 21-F introducer sheath using a designated delivery catheter with "telescope feature" for catheter extension 
Acute and 3-Month Performance of Leadless ATP Pacemaker and S-ICD -2 0 1 7 : ---hold the S-ICD stable for postural changes of the animal during communication testing.
The S-ICD uses 1 of 3 electrocardiographic recording "vectors" for heart rhythm discrimination. rate was above the programmed LP tachycardia lower limit (e.g., 155 beats/min) when the series of pulses is received, the LP will deliver ATP in accordance with its programmed parameters (i.e., scheme, coupling/ burst interval).
GROSS PATHOLOGY EXAMINATION.
In all chronic animals (n ¼ 13) killed after 90 days of follow-up, a gross pathological examination was performed to 
Acute and 3-Month Performance of Leadless ATP Pacemaker and S-ICD S-ICD heart rhythm discrimination was correct during intrinsic and LP pacing above the intrinsic rate and did not result in oversensing (Figure 3) . (Online Figure 4) . R-wave measurements were clipped at 25 mV. Several data points at different time
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Subcutaneous implantable cardioverter-defibrillator (S-ICD) rhythm discrimination during normal sinus rhythm (NSR) and during high-rate leadless pacemaker (LP)
pacing showing adequate rhythm discrimination in all 3 S-ICD-sensing vectors.
Acute and 3-Month Performance of Leadless ATP Pacemaker and S-ICD -2 0 1 7 : ---encapsulated. In none of the animals was substantial pericardial effusion (>10 ml) observed. In 3 animals Figure 1 .
Pacing threshold, V at 0. 
Pre-to post-shock change in pacing threshold, V at 0.5 ms
Pre-to post-shock change in impedance,
Values are n (%) or mean AE SD. *p value between baseline and 90 days, for pacing threshold and impedance tested with the Student t test, for R wave calculated with a linear regression analysis. †Pacing threshold data from 3 animals were excluded because the leadless pacemaker (LP) prototypes did not have steroid-eluting electrode. ‡Impedance and pacing threshold data from 1 animal were excluded due to suspected device malfunction at day 90. §R-wave and impedance data from 7 animals at baseline, 9 animals at day 7, and 7 animals at day 28 were excluded due to programmer software malfunction. Figure 3 .
